Hyundai Pharm (004310) - Cash Flow Conversion Efficiency

Latest as of February 2026: 0.001x

Based on the latest financial reports, Hyundai Pharm (004310) has a cash flow conversion efficiency ratio of 0.001x as of February 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩188.28 Million ≈ $127.59K USD) by net assets (₩134.81 Billion ≈ $91.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hyundai Pharm liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Hyundai Pharm - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Hyundai Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hyundai Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hyundai Pharm ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
DAEA TI Co. Ltd KQ:045390	-0.059x
Yungjin Pharm Co Ltd KO:003520	0.078x
Novonix Ltd ADR NASDAQ:NVX	-0.160x
Mobase Electronics Co.Ltd KQ:012860	0.082x
QuasarEdge Acquisition Corporation NYSE:QRED	N/A
AROBS TRANSILVANIA SOFTWARE SA RO:AROBS	N/A
Sandfire Resources America Inc V:SFR	0.050x
Emilia Devel TA:EMDV	0.063x

Annual Cash Flow Conversion Efficiency for Hyundai Pharm (2010–2025)

The table below shows the annual cash flow conversion efficiency of Hyundai Pharm from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see Hyundai Pharm market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-11-30	₩82.10 Billion ≈ $55.64 Million	₩-123.29 Million ≈ $-83.55K	-0.002x	+95.00%
2024-11-30	₩79.07 Billion ≈ $53.59 Million	₩-2.37 Billion ≈ $-1.61 Million	-0.030x	+44.10%
2023-11-30	₩84.66 Billion ≈ $57.37 Million	₩-4.55 Billion ≈ $-3.08 Million	-0.054x	-139.98%
2022-11-30	₩86.56 Billion ≈ $58.66 Million	₩11.62 Billion ≈ $7.88 Million	0.134x	+126.60%
2021-11-30	₩86.60 Billion ≈ $58.69 Million	₩5.13 Billion ≈ $3.48 Million	0.059x	-50.56%
2020-11-30	₩90.14 Billion ≈ $61.09 Million	₩10.80 Billion ≈ $7.32 Million	0.120x	+50.79%
2019-11-30	₩87.58 Billion ≈ $59.35 Million	₩6.96 Billion ≈ $4.72 Million	0.079x	+200.09%
2018-11-30	₩107.00 Billion ≈ $72.52 Million	₩2.83 Billion ≈ $1.92 Million	0.026x	+231.16%
2017-11-30	₩98.10 Billion ≈ $66.48 Million	₩-1.98 Billion ≈ $-1.34 Million	-0.020x	+26.42%
2016-11-30	₩100.08 Billion ≈ $67.82 Million	₩-2.75 Billion ≈ $-1.86 Million	-0.027x	-134.94%
2013-11-30	₩101.21 Billion ≈ $68.59 Million	₩7.95 Billion ≈ $5.39 Million	0.079x	+390.34%
2012-11-30	₩99.69 Billion ≈ $67.56 Million	₩-2.70 Billion ≈ $-1.83 Million	-0.027x	-145.03%
2011-11-30	₩104.32 Billion ≈ $70.69 Million	₩6.27 Billion ≈ $4.25 Million	0.060x	+107.53%
2010-11-30	₩92.50 Billion ≈ $62.69 Million	₩2.68 Billion ≈ $1.82 Million	0.029x	--

About Hyundai Pharm

KO:004310 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$159.23 Million

₩234.96 Billion KRW

Market Cap Rank

#17522 Global

#736 in Korea

Share Price

₩7600.00

Change (1 day)

+2.15%

52-Week Range

₩3415.00 - ₩14340.00

All Time High

₩14340.00